The neuronal component of gray matter damage in multiple sclerosis: A [11C]flumazenil positron emission tomography study

Annals of Neurology

Volumn 78, Issue 4, 2015, Pages 554-567

  Freeman, Léorah ^a,b,c,d   Garcia Lorenzo, Daniel ^a,e   Bottin, Laure ^a,b,c   Leroy, Claire ^c   Louapre, Céline ^a,b   Bodini, Benedetta ^a,b,c   Papeix, Caroline ^a,b   Assouad, Rana ^b   Granger, Benjamin ^b   Tourbah, Ayman ^f   Dollé, Frédéric ^c   Lubetzki, Catherine ^a,b,c,e   Bottlaender, Michel ^c   Stankoff, Bruno ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c DIF   (France)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e Institut des Neurosciences Translationnelles de Paris (IHU A ICM)   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; FLUMAZENIL; FLUMAZENIL C 11; CARBON;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN DAMAGE; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BINDING; FEMALE; FRONTAL CORTEX; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; INSULA; MALE; MULTIPLE SCLEROSIS; NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARIETAL CORTEX; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THALAMUS; WHITE MATTER; METABOLISM; MIDDLE AGED; ORGAN SIZE; PROCEDURES; SCINTISCANNING;

ADULT; CARBON RADIOISOTOPES; FEMALE; FLUMAZENIL; GRAY MATTER; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEURONS; ORGAN SIZE; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84942364958     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24468     Document Type: Article

References (82)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG,. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
2. Compston A, Coles A,. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
3. Barkhof F,. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999; 5: 283-286.
4. Bar-Zohar D, Agosta F, Goldstaub D, Filippi M,. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Mult Scler 2008; 14: 719-727.
5. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD,. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
6. Rudick RA, Trapp BD,. Gray-matter injury in multiple sclerosis. N Engl J Med 2009; 361: 1505-1506.
7. Geurts JJ, Calabrese M, Fisher E, Rudick RA,. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012; 11: 1082-1092.
8. Calabrese M, Battaglini M, Giorgio A, et al., Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology 2010; 75: 1234-1240.
9. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM,. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67: 960-967.
10. Cifelli A, Arridge M, Jezzard P, et al., Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52: 650-653.
11. Dutta R, Trapp BD,. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 2011; 93: 1-12.
12. Trapp BD, Nave KA,. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-269.
13. Vigeveno RM, Wiebenga OT, Wattjes MP, Geurts JJ, Barkhof F,. Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration. J Magn Reson Imaging 2012; 36: 1-19.
14. Seewann A, Kooi EJ, Roosendaal SD, et al., Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 2012; 78: 302-308.
15. Barkhof F, Calabresi PA, Miller DH, Reingold SC,. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-266.
16. Sailer M, Fischl B, Salat D, et al., Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003; 126 (pt 8): 1734-1744.
17. Fisher E, Lee JC, Nakamura K, Rudick RA,. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255-265.
18. Calabrese M, Rinaldi F, Grossi P, et al., Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler 2010; 16: 1220-1228.
19. Fisniku LK, Chard DT, Jackson JS, et al., Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64: 247-254.
20. Crespy L, Zaaraoui W, Lemaire M, et al., Prevalence of grey matter pathology in early multiple sclerosis assessed by magnetization transfer ratio imaging. PLoS One 2011; 6: e24969.
21. Hasan KM, Walimuni IS, Abid H, Wolinsky JS, Narayana PA,. Multi-modal quantitative MRI investigation of brain tissue neurodegeneration in multiple sclerosis. J Magn Reson Imaging 2012; 35: 1300-1311.
22. Derakhshan M, Caramanos Z, Narayanan S, Arnold DL, Louis Collins D,. Surface-based analysis reveals regions of reduced cortical magnetization transfer ratio in patients with multiple sclerosis: a proposed method for imaging subpial demyelination. Hum Brain Mapp 2014; 35: 3402-3413.
23. Filippi M, Bozzali M, Rovaris M, et al., Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126 (pt 2): 433-437.
24. Wylezinska M, Cifelli A, Jezzard P, et al., Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003; 60: 1949-1954.
25. Di Costanzo A, Trojsi F, Tosetti M, et al., Proton MR spectroscopy of the brain at 3 T: an update. Eur Radiol 2007; 17: 1651-1662.
26. Miller DH,. Magnetic resonance spectroscopy: a possible in vivo marker of disease progression for multiple sclerosis? JAMA Neurol 2014; 71: 828-830.
27. Mazière M, Prenant C, Sastre J, et al., [In vivo study of benzodiazepine receptors using positron emission tomography]. L'Encephale 1983; 9 (4 suppl 2): 151B-160B.
28. Möhler H,. Role of GABAA receptors in cognition. Biochem Soc Trans 2009; 37 (pt 6): 1328-1333.
29. Boecker H, Weindl A, Brooks DJ, et al., GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study. J Nucl Med 2010; 51: 1030-1035.
30. Hammers A, Panagoda P, Heckemann RA, et al., [11C]Flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling? J Cereb Blood Flow Metab 2008; 28: 207-216.
31. Heiss WD, Grond M, Thiel A, et al., Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke 1998; 29: 454-461.
32. Heiss WD, Kracht L, Grond M, et al., Early [(11)C]Flumazenil/H(2)O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy. Stroke 2000; 31: 366-369.
33. Klumpers UM, Veltman DJ, Drent ML, et al., Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging 2010; 37: 565-574.
34. Pinborg LH, Videbaek C, Hasselbalch SG, et al., Benzodiazepine receptor quantification in Huntington's disease with [(123)I]omazenil and SPECT. J Neurol Neurosurg Psychiatry 2001; 70: 657-661.
35. Turner MR, Hammers A, Al-Chalabi A, et al., Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain 2005; 128 (pt 6): 1323-1329.
36. Pascual B, Prieto E, Arbizu J, et al., Decreased carbon-11-flumazenil binding in early Alzheimer's disease. Brain 2012; 135 (pt 9): 2817-2825.
37. McDonald WI, Compston A, Edan G, et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
38. Rey A,. Psychological examination in cases of traumatic encephalopathy. L'examen psychologique dans les cas d'encephalopathie traumatique. Arch Psychol 1941; 28: 215-285.
39. Osterrieth PA,. The test of copying a complex figure: A contribution to the study of perception and memory. Filetest de copie d'une figure complex: contribution a l'etude de la perception et de la memoire. Arch Psychol 1944; 30: 206-256.
40. Spreen O, Strauss E,. A compendium of neuropsychological tests: administration, norms, and commentary. New York, NY: Oxford University Press, 1998.
41. Sureau FC, Reader AJ, Comtat C, et al., Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med 2008; 49: 1000-1008.
42. Delforge J, Spelle L, Bendriem B, et al., Quantitation of benzodiazepine receptors in human brain using the partial saturation method. J Nucl Med 1996; 37: 5-11.
43. Delforge J, Spelle L, Bendriem B, Samson Y, Syrota A,. Parametric images of benzodiazepine receptor concentration using a partial-saturation injection. J Cereb Blood Flow Metab 1997; 17: 343-355.
44. Bouvard S, Costes N, Bonnefoi F, et al., Seizure-related short-term plasticity of benzodiazepine receptors in partial epilepsy: a [11C]flumazenil-PET study. Brain 2005; 128 (pt 6): 1330-1343.
45. Chard DT, Jackson JS, Miller DH, Wheeler-Kingshott CA,. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging 2010; 32: 223-228.
46. Fischl B, Dale AM,. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000; 97: 11050-11055.
47. Dale AM, Fischl B, Sereno MI,. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999; 9: 179-194.
48. Fischl B, Sereno MI, Dale AM,. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999; 9: 195-207.
49. Fischl B, van der Kouwe A, Destrieux C, et al., Automatically parcellating the human cerebral cortex. Cereb Cortex 2004; 14: 11-22.
50. Fischl B, Salat DH, Busa E, et al., Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33: 341-355.
51. Greve DN, Fischl B,. Accurate and robust brain image alignment using boundary-based registration. Neuroimage 2009; 48: 63-72.
52. Greve DN, Svarer C, Fisher PM, et al., Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage 2014; 92: 225-236.
53. Kolasinski J, Stagg CJ, Chance SA, et al., A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain 2012; 135 (pt 10): 2938-2951.
54. Chen JT, Narayanan S, Collins DL, et al., Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 2004; 23: 1168-1175.
55. Charil A, Dagher A, Lerch JP, et al., Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. Neuroimage 2007; 34: 509-517.
56. Narayana PA, Govindarajan KA, Goel P, et al., Regional cortical thickness in relapsing remitting multiple sclerosis: a multi-center study. Neuroimage Clin 2012; 2: 120-131.
57. Eriksson SH, Free SL, Thom M, et al., Quantitative grey matter histological measures do not correlate with grey matter probability values from in vivo MRI in the temporal lobe. J Neurosci Methods 2009; 181: 111-118.
58. la Fougere C, Grant S, Kostikov A, et al., Where in-vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. Neuroimage 2011; 56: 951-960.
59. De Stefano N, Airas L, Grigoriadis N, et al., Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014; 28: 147-156.
60. Jacob TC, Moss SJ, Jurd R,. GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci 2008; 9: 331-343.
61. Rossi S, Muzio L, De Chiara V, et al., Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 2011; 25: 947-956.
62. Ziehn MO, Avedisian AA, Tiwari-Woodruff S, Voskuhl RR,. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 2010; 90: 774-786.
63. Centonze D, Muzio L, Rossi S, et al., Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009; 29: 3442-3452.
64. Cid MP, Vilcaes AA, Rupil LL, Salvatierra NA, Roth GA,. Participation of the GABAergic system on the glutamate release of frontal cortex synaptosomes from Wistar rats with experimental autoimmune encephalomyelitis. Neuroscience 2011; 189: 337-344.
65. Dutta R, Chomyk AM, Chang A, et al., Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol 2013; 73: 637-645.
66. Dutta R, McDonough J, Yin X, et al., Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-489.
67. Mandolesi G, Musella A, Gentile A, et al., Interleukin-1beta alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis. J Neurosci 2013; 33: 12105-12121.
68. Vercellino M, Merola A, Piacentino C, et al., Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 2007; 66: 732-739.
69. Chiaravalloti ND, DeLuca J,. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008; 7: 1139-1151.
70. Amato MP, Zipoli V, Portaccio E,. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006; 245: 41-46.
71. Louapre C, Perlbarg V, García-Lorenzo D, et al., Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study. Hum Brain Mapp 2014; 35: 4706-4717.
72. Calabrese M, Rinaldi F, Grossi P, Gallo P,. Cortical pathology and cognitive impairment in multiple sclerosis. Exp Rev Neurother 2011; 11: 425-432.
73. Blinkenberg M, Mathiesen HK, Tscherning T, et al., Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study. Neurol Res 2012; 34: 52-58.
74. Mathiesen HK, Jonsson A, Tscherning T, et al., Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol 2006; 63: 533536.
75. Forn C, Barros-Loscertales A, Escudero J, et al., Cortical reorganization during PASAT task in MS patients with preserved working memory functions. Neuroimage 2006; 31: 686-691.
76. Audoin B, Ibarrola D, Ranjeva JP, et al., Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. Hum Brain Mapp 2003; 20: 51-58.
77. Leech R, Sharp DJ,. The role of the posterior cingulate cortex in cognition and disease. Brain 2014; 137 (pt 1): 12-32.
78. Rocca MA, Valsasina P, Martinelli V, et al., Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology 2012; 79: 1449-1457.
79. Filippi M, Riccitelli G, Mattioli F, et al., Multiple sclerosis: effects of cognitive rehabilitation on structural and functional MR imaging measures-an explorative study. Radiology 2012; 262: 932-940.
80. Bissonette GB, Bae MH, Suresh T, Jaffe DE, Powell EM,. Prefrontal cognitive deficits in mice with altered cerebral cortical GABAergic interneurons. Behav Brain Res 2014; 259: 143-151.
81. Lewis DA,. Inhibitory neurons in human cortical circuits: substrate for cognitive dysfunction in schizophrenia. Curr Opin Neurobiol 2014; 26C: 22-26.
82. Sun B, Halabisky B, Zhou Y, et al., Imbalance between GABAergic and glutamatergic transmission impairs adult neurogenesis in an animal model of Alzheimer's disease. Cell Stem Cell 2009; 5: 624-633.